Certain individuals, particularly those with a history of medullary thyroid cancer or certain syndromes, pancreatitis, or severe gastrointestinal issues, may require alternative treatments
Individual response varies based on type of hair loss, follicle condition, and genetic factors
The dopamine-transporter SPECT substudy embedded in Exenatide-PD3 showed no separation between exenatide and placebo, mirroring the null clinical result and offering no imaging signal of preserved nigrostriatal terminals [2]
Still, the pharma aims to push tirzepatide into MASH
it's about improving mobility and mitigating health risks
CagriSema has prompted broader investigation of amylin-class compounds in combination with GLP-1 agonists, dual agonists, and triple agonists